Clinical trials: Female Breast Neoplasms
Vaginitis, Dyspareunia
Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.
Atrophic vaginitis is a condition in which the skin lining of the vagina and labia becomes thin and symptoms develop including vaginal itching, vaginal discomfort and dyspareunia.
- Conditions
- Vaginitis, Dyspareunia, Breast Neoplasms
- Trial name
- NCT01122342
- Testing
- Testosterone propionate
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Vermont
Breast Neoplasms
Effect of Kinesiotaping for the Treatment of Hormone-induced Myalgia in Women Given Breast Cancer Survivors
Background: It has been demonstrated that aromatase inhibitors (AIs) are more effective than tamoxifen in reducing breast cancer recurrence.
- Trial name
- KITMYCAN (NCT02406794)
- Testing
- Neuromuscular taping
- Where
- Spain
- Volunteers
- 156 people
- Sponsor
- University of Malaga
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Breast Cancer Invasive
Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)
DELFINO tial is designed to investigate the role of "OFS add on to TMX ", based on MMG density as a surrogate marker in premenopausal women Premise - MMG density as a surrogate marker of hormone therapy Assumption - "Add on OFS…
- Trial name
- NCT03664895
- Testing
- Leuplin or zoladex
- Where
- South Korea
- Volunteers
- 224 people
- Sponsor
- Seoul National University Hospital
Breast Cancer, Cervical Cancer
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episode in the 24 hours following their receipt of a message to increase…
- Conditions
- Breast Cancer, Cervical Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT07227077
- Testing
- Physical Activity Promotion Intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Medical College of Wisconsin
Breast Cancer
Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
Primary Objectives: Dose Escalation: To assess the incidence rate of dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) as well as the recommended dose (RD) of amcenestrant administered as monotherapy…
- Trial name
- AMEERA-1 (NCT03284957)
- Testing
- Amcenestrant, Palbociclib, Alpelisib
- Where
- 25 sites in United States, Belgium and 8 more
- Volunteers
- 136 people
- Sponsor
- Sanofi
Ovarian Cancer, AIDS-related Kaposi Sarcoma
Doxil/Caelyx BE Study
The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities.
- Conditions
- Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
- Trial name
- NCT05567601
- Testing
- DOXIL/CAELYX
- Where
- 14 sites in India
- Volunteers
- 36 people
- Sponsor
- Baxter Healthcare Corporation
Recurrent Breast Cancer, Stage IV Breast Cancer
Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
This phase II trial is to see if combining bevacizumab with docetaxel works in treating women who have locally advanced or metastatic breast cancer.
- Trial name
- NCT00055861
- Testing
- bevacizumab, docetaxel, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
This is a phase 2 study whose main purpose is to evaluate gene changes and immune biomarkers in patients with solid tumors during treatment with pembrolizumab and in relation to response to treatment.
- Conditions
- Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer, Epithelial Ovarian Cancer, Malignant Melanoma
- Trial name
- INSPIRE (NCT02644369)
- Testing
- Pembrolizumab
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Breast Cancer Related Lymphedema
Physiotherapy Program Impact on Breast Cancer-Related Lymphedema
Breast Cancer Related Lymphedema (BCRL) is a sequela resulting from the application of certain treatments, such as axillary lymph node dissection and regional lymph node radiation.
- Trial name
- NCT06491654
- Testing
- 12-week supervised exercise
- Where
- Spain
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- European University Miguel de Cervantes
Breast Cancer
Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00346229
- Testing
- filgrastim, pegfilgrastim, lyso-thermosensitive liposomal doxorubicin(Thermodox)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Duke University
Breast Cancer, BRCA1 Mutation
Endocrine Disruptors and Life STILe in Breast Cancer Development
The aim of the study is to evaluate the role of lifestyle and environmental factors ( environmental contaminants such as Cd) on the penetrance of BRCA1/2 genes in BRCAm patients with Breast cancer and/or Ovarian cancer and in…
- Conditions
- Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
- Trial name
- STILVARCA (NCT05748353)
- Where
- Italy
- Volunteers
- 275 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Healthy, no Evidence of Disease, Lobular Breast Carcinoma in Situ
Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
This randomized phase I trial studies the side effects and the best dose of letrozole in preventing breast cancer in healthy postmenopausal women at high risk for breast cancer.
- Trial name
- NCT01077453
- Testing
- letrozole, quality-of-life assessment, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Cancer, Metastatic Breast Cancer
Adaptation of a Values Assessment Tool
The primary purpose of this study is to evaluate the effect of values assessment tool on patient and caregiver perception of decisional conflict, and communication with their oncology clinician.
- Trial name
- NCT07068477
- Testing
- Values Assessment Tool
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Neoplasm Female
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
The management of HR-positive, HER2-negative metastatic breast cancer includes endocrine monotherapy or combination regimens, both with benefit diminishing as resistance develops.
- Trial name
- NCT05075512
- Testing
- anlotinib, fulvestrant
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer, Breast Cancer Female
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
The purpose of this study is to learn more about how to treat patients with HER-2/neu positive invasive breast cancer (IBC). HER-2/neu is a type of protein that is known to be over-expressed in aggressive breast cancer.
- Conditions
- Breast Cancer, Breast Cancer Female, Breast Cancer, Male, Invasive Breast Cancer
- Trial name
- NCT03387553
- Testing
- Dendritic Cell Vaccine (DC1), Neoadjuvant Chemotherapy, Curative Surgery
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Ovarian Neoplasms, Peritoneal Neoplasms
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine.
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms
- Trial name
- NCT05194072
- Testing
- Felmetatug Vedotin, Pembrolizumab
- Where
- 27 sites in United States, Canada and 3 more
- Volunteers
- 250 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Breast Cancer
Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer
RATIONALE: Screening tests such as ultrasound and mammography may help doctors detect cancer cells early and plan more effective treatment for breast cancer.
- Trial name
- NCT00072501
- Testing
- breast imaging study, comparison of screening methods, magnetic resonance imaging
- Where
- 20 sites in United States, Argentina and 1 more
- Sponsor
- American College of Radiology Imaging Network
Breast Cancer, Cardiovascular Complications
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure.
- Conditions
- Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01096381
- Testing
- laboratory biomarker analysis, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00032136
- Testing
- exemestane, tamoxifen citrate, adjuvant therapy
- Where
- United Kingdom
- Volunteers
- 4,400 people
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.